276 results on '"Abraham, Ivo"'
Search Results
2. Optimizing Postpartum Care in Rural Communities: Insights from Women in Arizona and Implications for Policy
3. A Least Absolute Shrinkage and Selection Operator-Derived Predictive Model for Postoperative Respiratory Failure in a Heterogeneous Adult Elective Surgery Patient Population
4. A LASSO-DERIVED PREDICTIVE MODEL FOR POSTOPERATIVE RESPIRATORY FAILURE IN A HETEROGENEOUS ADULT ELECTIVE SURGERY PATIENT POPULATION
5. Outcomes and risk factors for delayed-onset postoperative respiratory failure: a multi-center case-control study by the University of California Critical Care Research Collaborative (UC3RC)
6. Manuka combinations with nigella sativa and hydroxyurea in treating iron overload of pediatric β-thalassemia major, randomized clinical trial
7. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
8. The role of cytokines and Indolamine-2.3 dioxygenase in experiencing a psycho-neurological symptom cluster in hematological cancer patients: IL-1alpha, IL-1beta, IL-4, IL-6, TNF-alpha, kynurenine, and tryptophan
9. Biomarkers of gut barrier dysfunction in obstructive sleep apnea: A systematic review and meta-analysis
10. Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves.
11. Economic evaluation of the novel PD-1 inhibitor toripalimab in recurrent or metastatic nasopharyngeal carcinoma: Cost-efficiency and expanded access modeling versus pembrolizumab.
12. Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia
13. Neuropsychological Effects of Chemotherapy: Systematic Review of Longitudinal Studies on Objective Cognitive Impairment in Breast Cancer Patients
14. Association of chemotherapy and subjective cognitive impairment in breast cancer patients: Meta-analysis of longitudinal prospective cohort studies
15. Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis
16. Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma
17. No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)
18. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
19. The economic burden of Ebola virus disease: a review and recommendations for analysis
20. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves
21. Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)
22. Examining Risk of Heart Failures With Trastuzumab (Herceptin) Use Among Patients With HER2+ Breast Cancer Using Surveillance, Epidemiology, and End Results (Seer) Medicare: A Retrospective Cohort Study
23. Extended Medicaid coverage will improve access but insufficient to enhance postpartum care utilization: a secondary analysis of the 2016–2019 Arizona Medicaid claims
24. What to expect in 2024: important health economics and outcomes research (HEOR) trends
25. Polytomous Rasch Analyses of Surgeons' Decision-Making on Choice of Procedure in Endoscopic Lumbar Spinal Stenosis Decompression Surgeries.
26. What to expect in 2024: important health economics and outcomes research (HEOR) trends.
27. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma
28. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries
29. Preparing for the third decade of biosimilars
30. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region
31. The Changing Environment in Postgraduate Education in Orthopedic Surgery and Neurosurgery and Its Impact on Technology-Driven Targeted Interventional and Surgical Pain Management: Perspectives from Europe, Latin America, Asia, and The United States
32. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey
33. Proof-of-concept Study of Using Supervised Machine Learning Algorithms to Predict Self-care and Glycemic Control in Type 1 Diabetes Patients on Insulin Pump Therapy
34. Journal of Medical Economics in review: high impact articles from 2022
35. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: Simulation study
36. Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
37. The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer
38. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals
39. What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends
40. Optimizing Postpartum Care in Arizona
41. Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.
42. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention
43. Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment
44. Trends, Changes, and Disruptions: The Fragile Economics of Cancer Treatments
45. Racial/Ethnic, Sex, and Income Disparities in Overall Survival (OS) in Chronic Lymphocytic Leukemia (CLL) Patients in the Era of Targeted Therapy: Surveillance, Epidemiology, and End Results (SEER) Registry Analysis (2009-2019)
46. Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
47. sj-docx-1-aop-10.1177_10600280221146878 – Supplemental material for Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective
48. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan
49. Primary cutaneous melanoma in Black patients: An analysis of 2464 cases from the National Cancer Database 2004–2018
50. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.